Shareholders of Novo Nordisk A/S Advised to Join Class Action Against Company

Class Action Alert: Novo Nordisk A/S Investors

The Gross Law Firm has issued a warning for investors who suffered losses related to Novo Nordisk A/S (NYSE: NVO). If you purchased shares during the specified class period, you are highly encouraged to reach out to the firm as a potential lead plaintiff.

Important Details for Shareholders

The class action covers shares purchased between May 7, 2025, and July 28, 2025, when misleading statements were allegedly made by Novo Nordisk. According to the complaint, the company provided overly optimistic growth forecasts while hiding important adverse information that could significantly impact stock prices.

This misleading information included the company’s inflated claims about its ability to capitalize on the GLP-1 market, which turned out to be incorrect. On July 29, 2025, Novo Nordisk slashed its sales and profit projections for the remaining fiscal year, causing a severe stock price drop. Just one day prior, the stock closed at $69.00 per share, plunging by roughly 21.83% to $53.94 the following day. This dramatic decline illustrates the seriousness of the allegations made against Novo Nordisk, highlighting the risk posed to unsuspecting investors.

Next Steps for Investors

The Gross Law Firm suggests that shareholders who think they may qualify register as soon as possible. The deadline to apply for lead plaintiff status is September 30, 2025. Being a lead plaintiff isn't necessary to join the class action or obtain any recovery resulting from it.

Once registered, investors will be enrolled in a monitoring system that provides regular updates on the case’s progress, ensuring they are kept informed throughout the legal process. It’s essential for investors to act without delay to safeguard their interests.

Why Choose The Gross Law Firm?

The Gross Law Firm has built a reputation as a nationally recognized class action legal firm committed to protecting the rights of investors. They pursue justice for those affected by fraudulent activities and deceptive business practices. With their expertise and proven track record, the firm aims to hold corporations accountable for misleading their shareholders.

If you are an investor adversely impacted by Novo Nordisk’s actions, don’t hesitate to contact The Gross Law Firm at their New York office or visit their official website to learn more about your legal options.